Screener
Vaxcyte, Inc. PCVX Total Operating Expenses
Total Operating Expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $312,779 | $148,134 |
| General and administrative | 33,071 | 32,659 |
| Total operating expenses | 345,850 | 180,793 |
| Loss from operations | (345,850) | (180,793) |
| Other income, net: | ||
| Interest income | 26,610 | 32,935 |
| Other income (expense) | (1,382) | 7,140 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s total operating expenses?
- Vaxcyte, Inc. (PCVX) reported total operating expenses of $345.85M in Q1 2026.
- How has Vaxcyte, Inc.'s total operating expenses changed year-over-year?
- Vaxcyte, Inc.'s total operating expenses increased by 91.3% year-over-year, from $180.79M to $345.85M.
- What is the long-term trend for Vaxcyte, Inc.'s total operating expenses?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s total operating expenses has grown at a 72.8% compound annual growth rate (CAGR), from $103.67M to $923.68M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Vaxcyte, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude